Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bayer HealthCare has announced that the patient enrollment has commenced for Resorce (Regorafenib after Sorafenib in Patients with Hepatocellular Carcinoma), a phase III trial to assess the efficacy and safety of Stivarga (regorafenib) tablets for the treatment of patients with hepatocellular carcinoma (HCC), who have progressed on Nexavar (sorafenib) tablets.
Subscribe to our email newsletter
Nexavar (sorafenib) tablet is an anticancer medicine for the treatment of patients with unresectable HCC.
Stivarga is an inhibitor of multiple kinases involved in normal cellular functions and in pathologic processes such as oncogenesis, tumor angiogenesis and maintenance of the tumor microenvironment.
Bayer HealthCare Pharmaceuticals US Medical Affairs MD, vice president and head Pamela Cyrus said, "There is an unmet need for HCC patients whose disease has progressed after treatment with sorafenib, the only oral systemic therapy shown to improve overall survival in patients with unresectable HCC."